Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?

·4 min read

Biogen's (NASDAQ: BIIB) history so far with Alzheimer's disease drug Aduhelm is like a biotech soap opera. In this Motley Fool Live video, recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss whether the company will be able to move past all of the drama surrounding its controversial drug. Corinne Cardina: Let's dig into the Biogen issue a little bit more.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting